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Br J Pharmacol. 2019;1–20.Histamine, acting via distinct histamine H1, H2, H3, and H4 receptors, regulates vari-
ous physiological and pathological processes, including pain. In the last two decades,
there has been a particular increase in evidence to support the involvement of H3
receptor and H4 receptor in the modulation of neuropathic pain, which remains
challenging in terms of management. However, recent data show contrasting effects
on neuropathic pain due to multiple factors that determine the pharmacological
responses of histamine receptors and their underlying signal transduction properties
(e.g., localization on either the presynaptic or postsynaptic neuronal membranes). This
review summarizes the most recent findings on the role of histamine and the effects
mediated by the four histamine receptors in response to the various stimuli associ-
ated with and promoting neuropathic pain. We particularly focus on mechanisms
underlying histamine‐mediated analgesia, as we aim to clarify the analgesic potential
of histamine receptor ligands in neuropathic pain.1 | NEUROPATHIC PAIN AND ITS
TREATMENT
Neuropathic pain was first defined by the International Association for
the Study of Pain as “pain initiated or caused by a primary lesion
or dysfunction in the nervous system” (Merskey & Bogduk, 1994).
Fourteen years later, Treede et al. (2008) revised this definition and
redefined it as “pain arising as a direct consequence of a lesion or dis-
ease affecting the somatosensory system.” In the revised definition of
neuropathic pain, two terms have received particular attention. First,
the term “disease” which refers to all types of abnormal conditions
including inflammation, autoimmune syndromes, and ion channel dis-
orders (channelopathies) replaced the term “dysfunction.” Second, to
avoid misdiagnosis of neuropathic pain as another type of pain origi-
nating from the nervous system, such as spasticity and rigidity of the
muscles and bone (e.g., musculoskeletal pain), the term “nervous sys-
tem” was replaced by the term “somatosensory system” (Finnerup
et al., 2016). This revised definition of neuropathic pain describes- - - - - - - - - - - - - - - - - - - - - - - - - -
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ce Pthe nature of this condition more precisely and is, therefore, now
widely accepted and approved by the Neuropathic Pain Special Inter-
est Group of the International Association for the Study of Pain. Neu-
ropathic pain can be divided into two subtypes, peripheral or central,
based on the anatomical location of the lesion or the disease, within
the peripheral nervous system (PNS) or central nervous system
(CNS), respectively.
It is estimated that the worldwide prevalence rate of neuropathic
pain in the general population lies between 7% and 10%; however,
this figure differs for different countries (van Hecke, Austin, Khan,
Smith, & Torrance, 2014). The highest prevalence rates for neuro-
pathic pain were recorded in Canada (17.9%) and in the United States
(9.8–12.4%; VanDenKerkhof et al., 2016; Yawn et al., 2009), while a
relatively low prevalence rate was noted in Austria and Netherlands
(3.3% and 1%, respectively; Bouhassira, Lanteri‐Minet, Attal, Laurent,
& Touboul, 2008; Gustorff et al., 2008; Harifi et al., 2013). In the
United Kingdom, France, and Brazil, it is reported that 7–10% of
chronic pain sufferers have been affected by neuropathic pain (Fayaz,- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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2 OBARA ET AL.BJPCroft, Langford, Donaldson, & Jones, 2016). As a consequence
of extended life expectancy, it is predicted that the worldwide preva-
lence rate of neuropathic pain is likely to increase further, because
this type of chronic pain occurs with many common age‐related
diseases. Neuropathic pain is triggered by a lesion within the somato-
sensory system, trauma, or to toxic effects of certain medications
(Colloca et al., 2017; Yu et al., 2013). Pathological conditions that
are responsible for the development of neuropathic pain through
injury include metabolic diseases (e.g., diabetic neuropathy), infection
(e.g., postherpetic neuralgia), vascular disease (e.g., stroke), trauma
(e.g., orofacial neuropathy), and cancer (Campbell & Meyer, 2006).
Neuropathic pain is a complex condition that can either be constant
or periodic and presents with a range of different symptoms. These
symptoms can increase throughout the day with clinically relevant
morning–evening differences and can be affected by gender and
underlying aetiology (Gilron, Bailey, & Vandenkerkhof, 2013). Suf-
ferers of neuropathic pain have ongoing, spontaneous pain that has
a significant negative impact on quality of life and daily functioning,
including physical, emotional, and social well‐being (Jensen, Chodroff,
& Dworkin, 2007).
The mechanisms underlying neuropathic pain are complex and
multidimensional. Numerous pathophysiological and biochemical
changes cause morphological and functional adaptations in the ner-
vous system, including an increase in excitatory neurotransmitters
and neuropeptides, for example, histamine, bradykinin, 5‐HT, and glu-
tamate, which leads to hyperexcitability (Baron, Binder, & Wasner,
2010). Likewise, injured peripheral nerve fibres give rise to an intense
and prolonged input of ectopic activity to the CNS and may induce
secondary changes to the excitability of the spinal cord dorsal horn
neurons (Colloca et al., 2017; Ossipov & Porreca, 2005). These mor-
phological changes and functional adaptations lead to abnormal
sensory signs in patients with neuropathic pain presented as, for
example, allodynia (pain due to a stimulus that does not normally
activate the nociceptive system), hyperalgesia (an increased response
to a stimulus that is normally painful), or sensory loss (hypoesthesia).
Clinically, neuropathic pain manifests as evoked pain and presents in
many ways such as burning, tingling, prickling, shooting, electric
shock‐like, jabbing, squeezing, spasm, or cold (Rice, Finnerup, Kemp,
Currie, & Baron, 2018).
Animal models of neuropathic pain are essential in understanding
the plethora of mechanisms that may drive neuropathic pain, allowing
the field to identify potential therapeutic targets for the effective
management of this condition. Extensive research in the pain field
has developed and characterized a wide variety of animal models of
neuropathic pain. The four most commonly used models, also adopted
in some studies discussed in this review, are chronic constriction injury
(Bennett & Xie, 1988), partial sciatic ligation (Seltzer, Dubner, & Shir,
1990), spinal nerve ligation (Kim & Chung, 1992), and spared nerve
injury (Decosterd & Woolf, 2000) models. These models aim to simu-
late some of the clinical features of neuropathic pain, in the preclinical
setting (e.g., allodynia and hyperalgesia), because a large proportion of
peripheral neuropathic pain models, which are currently used in
research, share alterations in hind‐limb cutaneous sensory thresholdsfollowing partial injury of a peripheral (usually sciatic) nerve. This is
associated with the development of neuropathic pain symptoms, such
as hyperalgesia and allodynia (Ma et al., 2003; Wall et al., 1979). There
are also limitations associated with the use of animal models of neuro-
pathic pain. These limitations are linked to challenges associated with
(a) reliable and objective measures of behavioural responses to nox-
ious stimuli, since animals cannot self‐report and the experimenter
can be biased, (b) appropriateness of the outcome measures, for exam-
ple, sleep disturbance to reflect spontaneous pain, and (c) complexity
of mechanisms underlying the development of neuropathic pain and
their relevance to humans (Colleoni & Sacerdote, 2010).
Despite advances in the understanding of the underlying causes
and mechanisms leading to the development and maintenance of
neuropathic pain, 40% of Europeans who suffer from chronic pain
did not achieve satisfactory pain control (Breivik, Collett, Ventafridda,
Cohen, & Gallacher, 2006), and to date, no medication has shown
long‐term efficacy and tolerability for neuropathic pain conditions. A
significant contributing factor to these limited therapeutic strategies
is that neuropathic pain has different aetiology and pathophysiology
to any other type of chronic pain, making the management of this
type of chronic pain particularly difficult and challenging (Finnerup
et al., 2015). Consequently, there is a pressing need for the
identification of new therapeutic strategies to improve management
of neuropathic pain that will directly improve the outcome for pain
sufferers.
The histamine system has been a target for multiple therapeutic
interventions. Recently, growing evidence has supported the use of
selective ligands of histamine H3 receptor and H4 receptor for the
treatment of neuropathic pain (Bhowmik, Khanam, & Vohora, 2012;
Chaumette et al., 2018; Popiolek‐Barczyk et al., 2018; Sanna, Mello,
Masini, & Galeotti, 2018). Approval in the European Union for the
use of pitolisant (Wakix™), an antagonist/inverse agonist of H3 recep-
tors for the treatment of narcolepsy (Kollb‐Sielecka et al., 2017), pre-
sents an opportunity to explore its clinical use for other conditions.
Consequently, it seems an appropriate time to reconsider the hista-
mine system as a therapeutic target for the management of neuro-
pathic pain. This review aims to summarize the most recent findings
on the role of histamine and its effects, mediated by different sub-
types of histamine receptors, on neuropathic pain, with particular
regard to the mechanisms underlying histamine‐mediated analgesia.2 | HISTAMINE, HISTAMINE RECEPTORS,
AND PAIN
2.1 | Histamine and pain
Histamine (2‐(4‐imidazolyl)‐ethylamine), one of the most extensively
studied amino acid‐derived neurotransmitters in the CNS and PNS, is
involved in various physiological and pathological processes, including
sleep‐waking cycle, homeostasis, synaptic plasticity, and learning
(Panula et al., 2015; Parsons & Ganellin, 2006; Pini, Obara, Battell,
Chazot, & Rosa, 2016). Histamine is synthesized from the amino acid
OBARA ET AL. 3BJPL‐histidine through oxidative decarboxylation via catalysis with the
histidine decarboxylase enzyme (Bodmer, Imark, & Kneubuhl, 1999;
Haas, Sergeeva, & Selbach, 2008) and is arguably the most pleiotropic
molecule in the human and animal body, being present in many cell
types (Lindskog, 2017). Histamine is released by neuronal and non‐
neuronal sources and is responsible for many physiological processes,
including the contraction of smooth muscles of the lungs, uterus, and
intestine, secretion of gastric acid in the stomach, and vasodilation,
and modulation of heart rate and contractility (Parsons & Ganellin,
2006). Histamine also functions as a neurotransmitter, within the
nervous system, regulating a variety of body functions, such as tem-
perature control, memory, wakefulness, and pain sensation (Panula &
Nuutinen, 2013).
Histamine is a key mediator in the processing of nociceptive infor-
mation, acting in an antinociceptive manner in the CNS while, con-
versely, in a nociceptive manner in the PNS (Khalilzadeh, Azarpey,
Hazrati, & Vafaei Saiah, 2018). In the PNS, histamine is released in
response to tissue injury/damage, and, through the sensitization of
polymodal nociceptors resulting in increased firing rates, it contributes
to the generation of pain hypersensitivity. In neuropathic pain, hista-
mine released in the periphery by mast cells has been shown to play
an important role in the development of hypersensitivity following
nerve injury. This pathological process is associated with recruitment
of macrophages and neutrophils, and as histamine is a powerful
chemoattractant of mast cells, it regulates this recruitment (Smith,
Haskelberg, Tracey, & Moalem‐Taylor, 2007; Zuo, Perkins, Tracey, &
Geczy, 2003). Interestingly, it was also observed that peripherally act-
ing histamine could interact with mechanisms underlying pruritus (itch)
and pain. Findings suggest that low concentrations of histamine, acting
on sensory neurons, produce pruritus with a high concentration lead-
ing to pain (Baron, Schwarz, Kleinert, Schattschneider, & Wasner,
2001; Hough & Rice, 2011; LaMotte, Simone, Baumann, Shain, &
Alreja, 1987; Parsons & Ganellin, 2006; Pini et al., 2016; Simone,
Alreja, & LaMotte, 1991). There is also evidence to show that
histamine‐induced itch can convert into pain associated with neuro-
pathic hyperalgesia (Baron et al., 2001). Indeed, multiple itch pathways
were identified indicating the presence of distinct itch‐generating
types of neuron, one responsible for transmitting itch sensation
and the other, ultimately, for transmitting pain (Usoskin et al., 2015).
In contrast to histamine activity in PNS, multiple behavioural
studies have shown that histamine injected directly into the various
brain areas (e.g., somatosensory cortex or hippocampus) attenuated
pain (Erfanparast, Tamaddonfard, Farshid, & Khalilzadeh, 2010;
Tamaddonfard & Hamzeh‐Gooshchi, 2014).
Histamine exerts its effects via four distinct GPCR subtypes: H1,
H2, H3, and H4 receptors. These receptors differ in their pharmacology
and signal transduction properties (Panula et al., 2015; Parsons &
Ganellin, 2006; Simons & Simons, 2011). Thus, histamine has differen-
tial effects on neuropathic pain dependent upon the histamine recep-
tor subtype it is bound to. As mentioned previously, this review aims
to summarize histamine‐mediated effects on neuropathic pain. There-
fore, the next sections of this review focus on mechanisms underlying
histamine‐mediated analgesia.2.2 | Histamine receptors and pain
Excitatory histamine receptor signalling in nociceptive pathways is
associated with increased pain symptoms (Gangadharan & Kuner,
2013; Mobarakeh et al., 2000), whereas inhibition of histamine
receptor signalling predominantly causes neuroprotective and
antinociceptive effects (Bhowmik et al., 2012; Chazot & Care, 2005;
Popiolek‐Barczyk et al., 2018). Different subtypes of histamine recep-
tors are expressed in both presynaptic and postsynaptic neuronal mem-
branes (Brown, Stevens, & Haas, 2001; Parsons & Ganellin, 2006;
Zhang et al., 2013). Presynaptic histamine receptors function as
autoreceptors or heteroreceptors providing either positive or negative
feedback regulation of neurotransmitter release from the axon
terminals into the synaptic cleft (Nieto‐Alamilla, Marquez‐Gomez,
Garcia‐Galvez, Morales‐Figueroa, & Arias‐Montano, 2016). It could be
concluded that the resultant excitatory or inhibitory physiological
effect of histamine receptors depends on the action of the neurotrans-
mitter and the subsequent downstream cascade.
Specificity of localization of histamine receptors in different parts of
the nervous system, on either presynaptic or postsynaptic membranes,
is determined by their physiological relevance (Parsons & Ganellin,
2006). Among the four subtypes of histamine receptors, H1 and H2
receptors are predominantly identified postsynaptically (Brown et al.,
2001; Connelly et al., 2009; Zhang et al., 2013), with the location of
the H4 receptor requiring further investigation (Connelly et al., 2009).
Cross‐desensitization and agonist‐induced heterodimerization of H1
and H2 receptors (Alonso et al., 2013) may suggest a possible partner-
ship between histamine receptors. Expression of H3 receptors was ini-
tially reported as exclusively presynaptic in the rat cerebral cortex
(Arrang, Garbarg, & Schwartz, 1983; Clark & Hill, 1996), while postsyn-
aptic expression of H3 receptors could not be completely excluded
(Nieto‐Alamilla et al., 2016). H3 receptors are predominantly expressed
in neurons and, together with H4 receptors, have higher affinity (nM
range) for histamine than H1 and H2 receptors (μM range; Parsons &
Ganellin, 2006). Expression of H3 and H4 receptors on the opposite
sides of the synaptic cleft may contribute to their effects in neuropathic
pain, although the neuronal topology of the H4 receptor still remains
controversial. The use of selective ligands for histamine receptors has
led to a better understanding of the physiological and pathophysiolog-
ical roles of these receptors. The next section summarizes the effects
produced by histamine receptor ligands on neuropathic pain.
Besides their presynaptic or postsynaptic localization, the physio-
logical effects of histamine receptors are, to a great extent, determined
by the type of guanine nucleotide‐binding proteins (G‐proteins) to
which they are coupled (Leung & Wong, 2017). The difference in
underlying signalling pathways may directly determine the effect on
pain perception produced by selective ligands, even when they act at
the same histamine receptor, as described below.
2.2.1 | H1 receptor
H1 receptors are excitatory receptors, which couple with Gq‐type pro-
teins, leading to downstream activation of PLC and hydrolysis of
FIGURE 1 Diagram illustrating histamine
receptor signalling—Gq pathway. Histamine
binds to histamine receptors (H1, H2, or H3
receptor subtypes) that are coupled with the
Gq‐type protein. Gq α subunit activates PLC
which hydrolyses phosphatidylinositol 4,5‐
bisphosphate (PIP2), subsequently producing
DAG, that remains in the inner leaflet of the
plasma membrane activating PKC, and water
soluble inositol triphosphate (IP3), which binds
to inositol triphosphate sensitive receptor
(IP3R) and stimulates Ca
2+ release from
endoplasmic reticulum. This intracellular Ca2+
forms a complex with calmodulin (CaM)
Ca2+CaM and induces PKC‐dependent
phosphorylation. This suppresses the activity
of potassium voltage‐gated channels type 7
(Kv7 channels), which depolarizes the neurons,
and leads to the augmentation of neuronal
excitability, which manifests as increased pain
symptoms
4 OBARA ET AL.BJPphosphatidylinositol 4,5‐bisphosphate (PIP2) to produce DAG and ino-
sitol triphosphate (IP3). DAG subsequently activates PKC at the mem-
brane, while IP3 diffuses and binds to IP3 receptors on the endoplasmic
reticulum to mobilize stored calcium (Ca2+). These changes cause PIP2
depletion and increased intracellular concentration of Ca2+. This
increased concentration of Ca2+ activates PKC‐dependent phosphory-
lation and forms a complex with calmodulin (Ca2+CaM), both of which
suppress potassium voltage‐gated type 7 (Kv7) channels (Figure 1),
leading to depolarization and increased nociception (Brown &
Passmore, 2009; Chen, Li, Hiett, & Obukhov, 2016).2.2.2 | H2 receptor
H2 receptors are postsynaptic, predominantly associated with AC via
coupling to Gs and, in a similar fashion to H1 and H3 receptors, Gq pro-
teins, both pathways initiating excitatory downstream signalling. Thus,
H2 receptor inhibition yielded efficient antinociceptive effects(Mojtahedin, 2016). Gs α subunit stimulates AC with consequent
augmented production of cAMP and consequent activation of PKA
(Brown et al., 2001). Elevated cAMP concentration up‐regulates
PKA, which as reported for hippocampal neurons, could activate ligand
gated α‐AMPA receptors with resultant depolarization and increase of
neuronal firing (Park et al., 2016). Also, as it was reported for after‐
hyperpolarization in enteric neurons, PKA inhibits small conductance
Ca2+‐activated potassium (KCa) channels with resultant augmented
neuronal excitability (Figure 2; Vogalis, Harvey, & Furness, 2003).2.2.3 | H3 receptor
Presynaptic H3 receptors are coupled with Gi (AC inhibitory) proteins
(Nieto‐Alamilla et al., 2016; Schlicker & Kathmann, 2017). Gi α
subunit‐mediated AC inhibition results in a decreased intracellular
concentration of cAMP and subsequent down‐regulation of PKA
(Nieto‐Alamilla et al., 2016). In sympathetic and sensory neurons, itFIGURE 2 Diagram illustrating histamine
receptor signalling—Gs pathway. Histamine
binds to the H2 receptor subtype that is
coupled with the Gs‐type protein. Gs α subunit
activates AC, with subsequent production of
cAMP, which then stimulates PKA. PKA‐
dependent phosphorylation activates ligand
gated α‐AMPA receptors, which open and
facilitate influx of Na+ and, less commonly,
Ca2+. PKA also suppresses K+ efflux through
small conductance Ca2+‐activated potassium
channels (SK channels). Both the activation of
AMPA receptors and inhibition of SK channels
depolarize the neurons, with consequent
augmentation of their excitability and
increased pain signalling
OBARA ET AL. 5BJPwas reported that H3 receptor activation stimulated dissociation of
Gi β and γ subunits from Gi α subunit, which then inhibited
voltage‐gated Ca2+ influx through N‐, P‐, and Q‐type Ca2+ channels
(Zamponi & Currie, 2013), and stimulated G protein‐coupled
inwardly rectifying potassium (Kir) channels (Luscher & Slesinger,
2010). Both mechanisms could hyperpolarize presynaptic neurons,
reduce neuronal excitability, and produce pain relief (Figure 3).
Besides the Gi pathway, postsynaptic activation of H3 receptors
was reported to stimulate PLC in a subpopulation of striatal neurons,
with subsequent activation of the IP3 pathway followed by increased
intracellular concentrations of Ca2+ (Rivera‐Ramírez et al., 2016). Thus,
it is analogous to the mechanisms described for H1 /H2 receptors
coupled to Gq proteins (Figure 1). Similarly, the H1 and H2 receptor
Gq cascade PLC signalling pathways modulate neuronal excitability
with resultant potential facilitation of pain sensitivity. Furthermore,
H3 receptor activation was established to inhibit glycogen synthase
kinase 3β (GSK3β) and MAPK/ERK pathways (Bongers et al., 2007;
Morita, Aida, & Miyamoto, 1983). These effects are translated via Gi
β and γ subunits (Lai et al., 2016), which up‐regulate the PI3K pathway
with subsequent production of phosphatidylinositol 3,4,5‐
triphosphate (PIP3) from PIP2, which results in the recruitment of
PKB (Akt). PKB is initially activated by phosphoinositide‐dependent
kinase 1 (PDK1) and mammalian target of rapamycin complex 2‐FIGURE 3 Diagram illustrating histamine
receptor signalling—Gi pathway. Histamine
binds to the histamine receptors (presynaptic
and postsynaptic H3 or H4 receptor subtypes)
that are coupled with Gi‐type protein. The Gi
α subunit inhibits AC with subsequent
suppression of cAMP production and
inhibition of PKA activity. Also, Gi β and γ
subunits can inhibit Ca2+ influx through
voltage‐gated N‐, P‐, and Q‐type Ca2+
channels and stimulate G protein‐coupled
inwardly rectifying potassium (GIRK) channels,
with resultant K+ efflux. Both effects on N‐
type Ca2+ and GIRK channels result in the
development of hyperpolarization,
attenuation of neuronal excitability, and
resultant pain relief. Besides Gi α subunit
effects, H3 receptor activation could produce
analgesic effects through Gi β and γ subunits,
which up‐regulate the PI3K pathway, with the
subsequent production of
phosphatidylinositol 2,4,5‐trisphosphate
(PIP3) from phosphatidylinositol 4,5‐
bisphosphate (PIP2). PIP3 recruits PKB (Akt),
which phosphorylates and inactivates
glycogen synthase kinase 3β (GSK3β). In
parallel, PKB (Akt)‐dependent
phosphorylation additionally activates the
MAPK/ERK cascade. The action on both
GSK3β and MAPK/ERK decreases neuronal
excitability, inhibits mechanisms of neuronal
inflammation, and, therefore, produces pain
reliefdependent phosphorylation (Dzamko, Zhou, Huang, & Halliday,
2014). PKB, via phosphorylation, inactivates GSK3β, which decreases
neuronal excitability (Paul et al., 2016), inhibits neuronal inflammation
(Maixner & Weng, 2013), and, subsequently, relieves pain. PKB‐
dependent phosphorylation that activates the MAPK/ERK cascade
was also reported to be a highly efficient neuroprotective mechanism
for chronic inflammatory and neuropathic pain (Cruz & Cruz, 2007;
Figure 3).
2.2.4 | H4 receptor
The role of H4 receptors in the nervous system is poorly understood
(Schneider & Seifert, 2016). H4 receptors are known to be coupled
to Gi proteins, and their downstream pathways are postulated to be
similar to those described for H3 receptors (Figure 3). Compared to
the other three types of histamine receptors, the H4 receptor is not
expressed abundantly in the CNS and PNS. By quantitative single‐cell
Ca2+ imaging, it was demonstrated that histamine induces a Ca2+
increase in a subset of sensory neurons (3–10%) via activation of the
H1 and H4 receptors as well as inhibition of the H3 receptor. It is
assumed that the decreased threshold in response to H3 receptor
antagonism, which accounts for the analgesic effect of H3 receptor
antagonists, activates H1 and H4 receptors on sensory neurons, which
6 OBARA ET AL.BJPin turn results in the excitation of histamine‐sensitive afferents and,
therefore, may result in a modulation of pain sensitivity (Rossbach
et al., 2011).3 | HISTAMINE RECEPTOR LIGANDS AND
NEUROPATHIC PAIN
3.1 | H1 and H2 receptor ligands and neuropathic
pain
The best‐known roles for the H1 receptor are regulation of vasodila-
tion and bronchoconstriction on multiple cell types, including endo-
thelial and smooth muscle cells, while the H2 receptor is primarily
involved in the modulation of gastric secretion on parietal cells
(Barocelli & Ballabeni, 2003; Simons, 2003). There is also evidence
for their expression in the nervous system, where they regulate some
neuronal functions (Haas et al., 2008; Kashiba, Fukui, & Senba, 2001;
Murakami et al., 1999).
Both H1 and H2 receptors have been implicated in the role of his-
tamine in nociception and chronic pain (Table 1). Interestingly, with
the discovery of H1 and H2 receptor ligands in the 1950s, controlled
clinical studies using these H1 and H2 receptor antagonists reported
mild analgesic activity and their potential as analgesic adjuvants, par-
ticularly in conditions where pain was induced by histamine. Most of
the clinical studies focused on diphenhydramine (first generation H1
receptor antagonist) and showed its analgesic potential in the treat-
ment of dysmenorrhea, atypical head and face pain, trigeminal neural-
gia, and thalamic syndrome (Rumore & Schlichting, 1986). In addition,
diphenhydramine, when combined with opioids, showed its potential
as an analgesic adjuvant in refractory cancer pain (Santiago‐Palma,
Fischberg, Kornick, Khjainova, & Gonzales, 2001). In addition to clini-
cal evidence for the analgesic potential of H1 and H2 receptor antago-
nists, preclinical studies identified the expression of H1 and H2
receptors in nociceptive pathways and, therefore, further supported
the roles of H1 and H2 receptors in the regulation of pain. There are
limited anatomical data available for H2 receptors, despite the report
of H2 receptor mRNA expression in human spinal cord (Murakami
et al., 1999). The potential involvement of H1 receptors in the modu-
lation of neuropathic pain has been investigated more extensively. In
studies using in situ hybridization techniques in the guinea pig, the
H1 receptor mRNA was shown to be expressed in about 15–20% of
the central trigeminal and lumbar dorsal root ganglion (DRG) neurons.
These sensory neurons are fundamental to nociceptive processes,
potentially responding to histamine by acting on H1 receptors. These
neurons are exclusively small in size and coexpress isolectin B4, but
not substance P (SP) or CGRP, suggesting characteristics of unmyelin-
ated C‐fibres involved in acute nociception. Interestingly, the potential
role of H1 receptors in the regulation of neuropathic pain sensitivity
can be explained by the marked (up to fourfold) increase in H1 recep-
tor expression in the mainly small‐sized DRG neurons, 1–5 days after a
crush injury of the sciatic nerve. Moreover, this study showed new
characteristics of peptidergic (SP/CGRP) sensory neurons notdetected prior to nerve injury, suggesting that the sensory modalities
evoked by histamine acting via H1 receptors in normal and neuro-
pathic pain states may result in different effects. This demonstration
of the potential up‐regulation of H1 receptor number in injured affer-
ent nerves further supports the involvement of H1 receptors in the
regulation of neuropathic pain hypersensitivity, presumably expressed
on unmyelinated C‐fibres (Kashiba et al., 2001). The earliest electro-
physiological study to probe the histaminergic system in neuropathic
pain transmission reported that daily injections of astemizole, a
CNS‐sparing H1 receptor antagonist, acting via peripheral histamine‐
sensitive C‐fibres, blocked ectopic spontaneous discharges from the
neuroma and suppressed autotomy following sciatic and saphenous
neurectomy (Seltzer et al., 1991; Yu et al., 2013). More recently, i.c.
v. injection of histamine blocked mechanical and thermal hypersensi-
tivity associated with neuropathic pain (Sanna et al., 2015; Wei
et al., 2016). However, these pain‐modulatory effects of histamine
can vary depending on the dose of histamine administered i.c.v., due
to an action on H2 receptors and the involvement of adrenoceptors
(Wei et al., 2014; Wei et al., 2016).
To further support the role of H1 and H2 receptors in the regula-
tion of pain, separate studies using knockout (KO) mice lacking H1
and H2 receptors demonstrated that these mice displayed significantly
lower responses to nociceptive stimuli when compared to their wild‐
type controls (Mobarakeh et al., 2002; Mobarakeh, Takahashi,
Sakurada, Kuramasu, & Yanai, 2006). Interestingly, the antinociceptive
phenotype of H2 receptor KO mice was relatively less prominent
when compared to H1 receptor KO mice, suggesting a potentially dis-
tinct role for these receptors in the modulation of pain. Indeed, behav-
ioural studies using a model of neuropathic pain, induced by the partial
ligation of the sciatic nerve, showed that the CNS‐permeable H1
receptor antagonist mepyramine, but not the H2 receptor CNS‐
sparing antagonist cimetidine, blocked the effects of histidine on neu-
ropathic pain hypersensitivity and spinal microglia activity (Yu et al.,
2016). In addition, Jaggi et al. (2017) suggested that the H1 receptor
plays a more important role in a vincristine‐induced model of neuro-
pathic pain, when compared to H2 receptors. However, Khalilzadeh
et al. (2018) observed different behavioural effects upon tibial nerve
transection‐induced neuropathic pain with respect to the extent of
brain penetration of the ligands, in a study focused on centrally
active and centrally sparing H1 and H2 receptor antagonists.
Specifically, both chlorpheniramine, a centrally and peripherally
active H1 receptor antagonist, and fexofenadine, an H1 receptor,
centrally sparing antagonist, were found to profoundly decrease
the mechanical hypersensitivity associated with the development of
neuropathic pain. In contrast, while ranitidine, a widely used cen-
trally permeable H2 receptor antagonist, also improved mechanical
hypersensitivity, famotidine, a centrally sparing H2 receptor antago-
nist, was ineffective. These results indicate that both blood brain
barrier penetrating and poorly penetrating histamine H1 receptor
antagonists can block neuropathic pain hypersensitivity, but only
the blood brain barrier penetrating histamine H2 receptor antagonist
can generate an analgesic effect in neuropathic pain. In line with
this observation, histamine‐induced mechanical hypersensitivity
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10 OBARA ET AL.BJPwas prevented by spinal pretreatment with zolantidine, a brain
penetrating H2 receptor antagonist, as well as localized peripheral
administration of cimetidine (H2 receptor antagonist) and chlorphen-
iramine (H1 receptor antagonist) into the plantar side of the hindpaw
(Zuo et al., 2003).
Taken together, these results indicate that the brain histamine,
acting particularly via central H1 and H2 receptors, may be involved
in the modulation of neuropathic pain. These studies consistently sup-
port the idea that CNS‐permeable H1 and H2 receptor antagonists
may potentially be used as analgesics for patients with neuropathic
pain. The involvement of central H2 receptors in the regulation of neu-
ropathic pain hypersensitivity was also demonstrated in studies where
histamine (presumably postsynaptically‐ induced) facilitated mechani-
cal hypersensitivity mediated by NMDA receptors as well as, in a
dose‐dependent manner, Nav1.8 channel expression in primary
afferent neurons in the sciatic nerve and L4/L5 DRG (Wei et al.,
2016; Yue et al., 2014). While sodium channels are responsible for
the development and maintenance of neuropathic pain (Ossipov &
Porreca, 2005; Yue et al., 2014), the above studies highlight the
importance of histamine acting via H2 receptors in the regulation of
mechanisms associated with neuropathic pain states. The influence
of the H2 receptor on non‐neuronal cells (mast cells) is discussed later
in this review.3.2 | H3 receptor ligands and neuropathic pain
H3 receptors are mostly presynaptic, expressed as autoreceptors on
histaminergic neurons involved in the negative feedback control
of histamine levels (Arrang et al., 1983; Hough & Rice, 2011), while
H3 heteroreceptors on postsynaptic nonhistaminergic neurons also
regulate negatively the release of neurotransmitters, such as ACh,
dopamine, 5‐HT, and noradrenaline (Blandina, Munari, Giannoni,
Mariottini, & Passani, 2010; Gemkow et al., 2009; Giannoni et al.,
2010). Since the cloning of H3 receptors (Lovenberg et al., 1999),
there has been an increased interest within the pharmaceutical indus-
try in developing ligands for this receptor to target several diseases,
including neuropathic pain. This interest was strongly fuelled by the
report of H3 receptor expression in nociceptive pathways, suggesting
its functional involvement in the regulation of nociceptive transmis-
sion (Cannon et al., 2007). Indeed, the histamine H3 receptor consists
of several functional isoforms expressed in both the CNS and PNS,
particularly along the ascending nociceptive pathway and descending
pain‐control pathway, that are critical for the processing of nocicep-
tive information. Within the CNS, this receptor has been found in var-
ious brain areas, such as thalamus, hypothalamus, prefrontal cortex,
and periaqueductal grey area (Drutel et al., 2001), and in the spinal
cord (Cannon et al., 2007; Heron, Rouleau, Cochois, Pillot, & Schwartz,
2001; Medhurst et al., 2008). In the periphery, the expression of H3
receptors has been identified in DRG, superior cervical ganglia, and
dermal tissues (Cannon et al., 2007; Medhurst et al., 2008).
However, while the localization of H3 receptors strongly suggests
its functional involvement in the regulation of nociceptive transmis-
sion, pharmacological studies using agonists and antagonists of H3receptors are confusing as these drugs have different effects on the
nociceptive threshold depending on the pain model used, the nocicep-
tive stimulus selected, together with the affinity and selectivity for the
histamine receptors, and the dose and routes of administration (Huang
et al., 2007; Smith et al., 2007). Several studies have reported inhibi-
tory effects on pain following activation of H3 receptors using agonists
(Cannon et al., 2003; Hasanein, 2011). The involvement of H3 recep-
tors in neuropathic pain has been implicated using a range of H3
receptor antagonists/inverse agonists (Table 1). The antagonism at
H3 receptors results in reduced mechanical and cold hypersensitivity
associated with neuropathic pain (chronic constriction injury model
or spinal nerve ligation model) as shown in studies using E‐162 or
GSK189254, selective H3 receptor antagonists, where its strong anal-
gesic effect was observed after a single systemic (i.p.) dose (Hsieh
et al., 2010; Popiolek‐Barczyk et al., 2018). In addition, repeated, orally
delivered doses of GSK189254, GSK334429, S38093, and A‐960656,
selective H3 receptor antagonists/inverse agonists, significantly
reduced paw withdrawal threshold to mechanical stimuli or elicited
an analgesic effect in the vocalization test of neuropathic pain (chronic
constriction injury model or spinal nerve ligation model), showing
comparable efficacy to pregabalin or gabapentin, which are both used
clinically as first‐line treatments (Chaumette et al., 2018; Cowart et al.,
2012; Medhurst et al., 2008). The analgesic efficacy of S38093 was
also confirmed in other models of neuropathic pain with different
aetiologies, such as diabetic and chemotherapeutic agent‐induced
neuropathy, where the drug again showed analgesic potency similar
to pregabalin and gabapentin (Chaumette et al., 2018). Analgesia
induced by the blockade of the H3 receptor is possibly the result of
the regulation of histamine levels in the CNS, as depolarization
activates histamine synthesis in nerve endings, a process that is con-
trolled by H3 autoreceptors (Arrang et al., 1983; Hough & Rice,
2011). Indeed, Wei et al. (2016) proposed that blocking the
autoinhibitory H3 receptor on histaminergic terminals in the pontine
locus coeruleus (LC), which receives efferent projections from the his-
taminergic tuberomammillary nucleus, facilitated endogenous release
of histamine leading to neuropathic hypersensitivity inhibition through
the regulation of descending noradrenergic pathways. In addition,
there is accumulating evidence to support the idea that the analgesic
effects of H3 receptor antagonists/inverse agonists in neuropathic
pain can be partially mediated by α2 adrenoceptor desensitization
(induced by H3 receptor antagonists/inverse agonists) in the LC
and spinal cord. This suggests an inhibitory role for the central
heteroreceptor noradrenergic transmission in the efficacy of H3 recep-
tor antagonists/inverse agonists. In agreement with this idea, systemic
administration of α2 adrenoceptor agonists or nerve injury‐induced
activation of these α2 adrenoceptors decreases the firing activity of
LC noradrenergic cells, resulting in the dampening of noradrenaline
release in the terminal area (e.g., prefrontal cortex or spinal cord) and
promoting neuropathic hypersensitivity by attenuating descending
inhibition (Chaumette et al., 2018; Wei et al., 2010; Wei et al.,
2014). In contrast, treatment with H3 receptor antagonists/inverse
agonists restores LC and decreases α2 adrenoceptor activity, respec-
tively, potentially leading to relief in neuropathic pain hypersensitivity
OBARA ET AL. 11BJP(Chaumette et al., 2018; Wei et al., 2010). To further support this
proposed mechanism, it was shown that bilateral lesion of the LC,
transection of the spinal cord, or direct injection of a α2 agonist
(fadolmidine) into the LC reversed the antihyperalgesic effect pro-
duced by H3 receptor antagonists, A‐960656 or GSK189254
(Chaumette et al., 2018; McGaraughty, Chu, Cowart, & Brioni,
2012; Wei et al., 2014). In line with this, electrophysiological studies
performed in anaesthetized animals indicated that, after systemic
administration, GSK189254 dose‐dependently decreased both
evoked and spontaneous firing of wide dynamic range neurons in
neuropathic, but not sham‐operated rats (McGaraughty et al.,
2012). However, analgesia induced by the blockade of the H3 recep-
tor can also be mediated via H3 heteroreceptors that regulate other
neurotransmitters' release; the blockade of the H3 receptor is known
to increase the release of ACh, dopamine, 5‐HT, noradrenaline, and
SP in the CNS (Blandina et al., 2010; Gemkow et al., 2009; Giannoni
et al., 2010).
Interestingly, the majority of the behavioural observations pub-
lished indicate that H3 receptor antagonists/inverse agonists do not
produce any antinociceptive effects in naïve rodents, suggesting a pos-
sibility that H3 receptors are not involved or tonically activated in
nociception (at least in relation to acute mechanical nociception), but
are critical for pathological pain states, particularly for mechanical
hypersensitivity (Chaumette et al., 2018; McGaraughty et al., 2012).
Also, H3 receptor KO mice showed unaltered response to mechanical
pinch (Cannon et al., 2003), and multiple studies suggest modality
(mechanical vs. heat) and intensity (preferential responses to low‐
intensity tail pinch stimulation; Cannon et al., 2003) with specific
antinociceptive effects mediated by H3 receptors. H3 receptor
antagonists/inverse agonists at a dose that produced a significant
reduction of mechanical hypersensitivity in neuropathic pain did not
attenuate heat hypersensitivity indicating that the antihyperalgesic
effect was due to selective depression of spinal sensory rather than
motor neurons (Wei et al., 2014; Wei et al., 2016). To support this,
in situ hybridization studies revealed H3 receptor mRNA transcripts
in the sensory neurons of the dorsal horn and DRG (Heron et al.,
2001). Moreover, receptor autoradiography studies, using [3H]
GSK189254, showed specific H3 receptor binding sites in the
dorsal horn of the spinal cord and DRG, confirming these as sites
of action of H3 receptor antagonists within structures receiving
histaminergic innervation and are critical for processing of pain infor-
mation (Medhurst et al., 2008). The modality‐ and intensity‐specific
antinociceptive effects of H3 receptor activation/inhibition may also
suggest involvement of a specific population of sensory fibres that
regulate mechanical hypersensitivity. In line with this, immunohisto-
chemical studies identified localization of H3 receptors (confirmed by
H3 receptor KO mice) on medium‐size cell bodies in DRG and on
small‐calibre periarterial, peptidergic Aδ fibres that ramified in dorsal
horn laminae I, II, and V and coexpress immunoreactivity for acid‐
sensing ion channel 3 and 200‐kD neurofilament protein. This strongly
supports the involvement of H3 receptors in the regulation of mechan-
ical sensitivity (Cannon et al., 2007). In addition, Medhurst et al. (2007)
showed that GSK207040 and GSK334429, selective H3 receptorantagonists, blocked the secondary mechanical allodynia in the
capsaicin‐induced model of pain. Secondary mechanical hypersensitiv-
ity is known to be exclusively signalled by A‐fibres and amplified by
sensitized dorsal horn neurons (Magerl, Fuchs, Meyer, & Treede,
2001; Treede & Magerl, 2000). Thus, presumably reducing the sensi-
tivity of H3 receptor‐positive A‐fibres with selective H3 receptor
antagonists resulted in a diminished input to the dorsal horn and the
subsequent amplification of the A‐fibres response, confirming the
potential role for H3 receptors in the modulation of central sensitiza-
tion processes. In contrast, thermal (heat) hypersensitivity is generally
regarded as a sign of the peripheral sensitization of C‐fibres, which do
not express H3 receptors (Cannon et al., 2007; Gold & Gebhart, 2010).
The only study that reported a significant increase in thermal (radiant
heat in Hargreaves test), but not mechanical, threshold in the spared
nerve injury model of neuropathic pain used the selective H3 receptor
inverse agonist pitolisant (Wakix™). The drug produced this unex-
pected effect at a dose 5× higher than its clinically relevant dose,
and pharmacological analysis of this effect suggested at least partial
involvement of transient receptor potential cation channel subfamily
V member 1 (TRPV1), without any contribution of H3 receptors
(Zhang et al., 2012). Interestingly, the H3 receptor antagonist/inverse
agonist E‐162, at a dose that produced a significant reduction in
mechanical hypersensitivity, also attenuated the response to cold in
neuropathic pain (Popiolek‐Barczyk et al., 2018). The signalling of cool
temperatures that become aversive in neuropathic pain is known to be
mediated via the TRPM8 receptor, a member of the TRP channel fam-
ily (Knowlton et al., 2013). It was reported that the number of TRPM8‐
positive Aδ‐fibres (but not C‐fibres) increases after nerve injury (Ji,
Zhou, Kochukov, Westlund, & Carlton, 2007); thus, it is possible that
H3 receptor‐positive A‐fibres are probably sensitive to cooling and
may contribute to cold hypersensitivity in neuropathic pain.
The most significant inconsistencies in behavioural outcomes
in neuropathic pain can be found in studies on the role of a first‐
generation imidazole‐based molecule, thioperamide (H3 receptor
antagonist, H3 /H4 receptor inverse agonist), in the regulation of
mechanical hypersensitivity in neuropathic pain. On the one hand,
blocking H3 receptors (and H4 receptors) by thioperamide resulted in
a significant enhancement of mechanical hyperalgesia in a rat model
of neuropathic pain induced by partial ligation of the sciatic nerve.
Specifically, i.c.v. (Huang et al., 2007) or s.c. injection (Smith et al.,
2007) of thioperamide directly into the operated hindpaw resulted in
a significantly reduced mechanical withdrawal threshold as compared
to controls. On the other hand, systemic (i.p.) injection of thioperamide
significantly increased mechanical withdrawal threshold indicating an
analgesic effect (Huang et al., 2007). The reason for this discrepancy
may lie in the drug's dual affinity for both H3 and H4 receptors (e.g.,
the effect of thioperamide on neurotransmitter release in the anterior
hypothalamic area of rats is nonreversible by an H3 receptor agonist,
suggesting the involvement of H4 receptors; Yamamoto, Mochizuki,
Okakura‐Mochizuki, Uno, & Yamatodani, 1997) and on the behav-
ioural effects resulting from the route (localized vs. systemic) and
dose of thioperamide administration. In addition, the involvement of
other histaminergic mechanisms of action in the behavioural effects
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thioperamide increases the density of intact mast cells in the injured
nerve (Smith et al., 2007). While nerve injury causes a decrease in
mast cell numbers as a consequence of degranulation (Zuo et al.,
2003), thioperamide's action leads to an opposite effect that may rep-
resent a prevention of mast cell degranulation and stabilization or
redistribution of mast cells in the injured nerve that theoretically
would result in the inhibition of hyperalgesia, rather than its enhance-
ment. This effect could be linked to the observation that histamine
(acting through H1 and H3 receptors) inhibits the release of the pro‐
inflammatory cytokine TNF‐α from alveolar macrophages (Sirois,
Ménard, Moses, & Bissonnette, 2000), and antagonism of H3 recep-
tors on macrophages resulted in an increase inTNF‐α and, subsequent,
enhancement of mechanical hyperalgesia (Smith et al., 2007).
Taken together, the interpretation of the thioperamide data is
complicated further since the drug has high affinity, not only for H3
and H4 receptors but also for 5‐HT3 receptors (Leurs et al., 1995).
Studies with more selective H3 receptor antagonists/inverse agonists
suggest that these ligands may be beneficial for the improvement of
mechanical and cold hypersensitivity associated with neuropathic
pain, particularly given their ability to modulate histamine levels, as
well as several neurotransmitters, including ACh, histamine, noradren-
aline, dopamine, and SP. However, due to the wide presynaptic and
postsynaptic distribution of H3 receptors throughout the CNS and
PNS, more research is certainly needed to clarify the involvement of
peripheral, spinal, and brain H3 receptors in various neuropathic pain
states, thus determining their full potential in neuropathic pain.
3.3 | H4 receptor ligands and neuropathic pain
The H4 receptor, which has low homology with other histamine recep-
tors, can be primarily found in bone marrow, intestinal tissue, spleen,
thymus, and also in various immune cells, such as T cells, mast cells,
neutrophils, and eosinophils, showing modulatory effects on these
cells, including activation, migration, and production of cytokines
and chemokines, suggesting its principal role in the regulation of
immune/inflammatory mechanisms (Takeshita, Sakai, Bacon, &
Gantner, 2003; Zhu et al., 2001). Interestingly, recent reports also indi-
cate the presence of H4 receptors on peripheral sensory nerves, in the
DRG, with more intense staining of small‐ and medium‐diameter cells,
and in the spinal cord, especially laminae I and II (Sanna, Lucarini, et al.,
2017; Strakhova et al., 2009). This neuronal localization supports H4
receptors involvement in the regulation of neuronal function related
to the modulation of nociceptive transmission (Sanna, Ghelardini,
Thurmond, Masini, & Galeotti, 2017; Sanna, Lucarini, et al., 2017).
The involvement of H4 receptors in both acute (Galeotti, Sanna, &
Ghelardini, 2013) and persistent inflammatory pain (Hsieh et al., 2010)
is relatively well documented, and recently, the role of H4 receptors in
the modulation of neuropathic pain was identified in H4 receptor‐KO
mice through the observation that these animals, when subjected to
neuropathic pain, induced by spared nerve injury of sciatic nerve,
showed enhanced hypersensitivity to mechanical and thermal stimuli
compared to wild‐type controls (Sanna, Ghelardini, et al., 2017).Interestingly, H4 receptor deficiency does not support a role for H4
receptors in the physiological maintenance of pain threshold, as H4
receptor‐KO mice did not show any change in thermal or mechanical
nociceptive thresholds, suggesting that the H4 receptor is specifically
involved in the regulation of hypersensitivity associated with patho-
logical chronic pain induced by nerve injury (Sanna, Ghelardini, et al.,
2017). This observation in H4 receptor‐KO neuropathic mice is partic-
ularly important as H4 receptor mRNA expression in humans and
rodents supports their involvement in the regulation of neuronal func-
tion, including regulation of neuropathic pain. The controversy around
the generation of consistently specific H4 receptor antibodies high-
lights the need for cautious interpretation of some of the immunohis-
tochemical outcomes (Beermann, Seifert, & Neumann, 2012; Gutzmer
et al., 2012; Schneider & Seifert, 2016). In line with the observation
from H4 receptor KO mice, blockade of H4 receptors by the specific
H4 receptor antagonist JNJ7777120, injected s.c. directly into the
operated hindpaw, resulted in a significant increase in mechanical
hyperalgesia compared to controls (Smith et al., 2007). Subsequently,
activation of H4 receptors by localized administration of potent and
selective agonists, ST‐1006 (i.c.v.) and VUF8430 (i.c.v., intrathecally,
and s.c. directly into the operated hindpaw), resulted in a significantly
reduced mechanical and thermal withdrawal threshold in mice sub-
jected to neuropathic pain induced by spared nerve injury or partial
nerve ligation of the sciatic nerve (Sanna et al., 2015; Sanna, Lucarini,
et al., 2017; Smith et al., 2007). The analgesia produced by VUF8430
has been shown to be associated with a reduction in neuroinflamma-
tion and oxidative stress mediated by neuronal H4 receptors in the
spinal cord and sciatic nerve (Sanna, Lucarini, et al., 2017), and
the involvement of H4 receptors in the behavioural effects produced
by ST‐1006 and VUF8430 was confirmed with JNJ10191584, H4
receptor antagonist also known as VUF6002, which fully prevented
the analgesic effects produced by these H4 receptor agonists (Sanna
et al., 2015).
Interestingly, similar to the H3 receptor, pharmacological studies
using agonists and antagonists of H4 receptors demonstrate that these
drugs can have different effects on the nociceptive threshold depend-
ing on the routes of administration and target cells (Popiolek‐Barczyk
et al., 2018; Sanna et al., 2015). In contrast to the studies above that
used H3 receptor agonists/antagonists after localized application, the
antagonism of H4 receptors produced by systemic administration
resulted in the alleviation of mechanical and cold hypersensitivity
associated with neuropathic pain (chronic constriction injury model).
Studies usingTR‐7, a selective H4 receptor antagonist, elicited a strong
analgesic effect after a single systemic (i.p.) dose, which was as effec-
tive as morphine, a gold standard in pain treatment (Popiolek‐Barczyk
et al., 2018). In addition, JNJ7777120 reduced mechanical hypersensi-
tivity after a systemic (i.p.) administration in neuropathic pain (chronic
constriction injury model and spinal nerve ligation model; Hsieh et al.,
2010). Given that H4 receptors are expressed on the immune cells, in
addition to the well‐documented involvement of H4 receptors in the
regulation of immune/inflammatory mechanisms (Takeshita et al.,
2003; Zhu et al., 2001), it is possible that the antinociceptive action
of H4 receptor antagonists, particularly after systemic administration,
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site of nerve injury, since the analgesic effect produced by
JNJ7777120 was weaker (secondary) than its anti‐inflammatory effect
(Hsieh et al., 2010). An underlying mechanism may be associated with
stabilization of mast cells that are known to regulate the recruitment
of neutrophils and macrophages and, subsequently, to modulate the
development of hyperalgesia in neuropathic pain (Smith et al., 2007;
Zuo et al., 2003). It should be further noted that similar observations
have been described for the closely related H3 receptor.
The H4 receptor is known to activate the MAPK signalling pathway
in mast cells (Desai & Thurmond, 2011). Interestingly, Sanna et al.
(2015, 2018) also identified the effect of H4 receptor stimulation on
the activity of the MAPK signalling pathway in neurons. They demon-
strated that modulation of this signalling pathway within the neurons
of the DRG, spinal cord, and sciatic nerve underpinned H4 receptor
agonist‐induced antiallodynic activity. They also revealed that neuro-
pathic pain hypersensitivity observed in H4 receptor‐KO mice is asso-
ciated with an overactivation of the spinal ERK–cAMP response
element‐binding protein pathway in DβH immunoreactive neurons,
supporting a potential association between the noradrenergic system
and H4 receptor‐mediated analgesia. In summary, increasing evidence
arising from H4 receptor KO mice and the use of selective ligands sup-
port H4 receptor as an interesting neuronal target for the treatment of
chronic, particularly neuropathic, pain.4 | HISTAMINE AND NON‐NEURONAL
CELLS IN NEUROPATHIC PAIN
Following peripheral nerve injury, the immune system seems to play a
vital role in the development of persistent inflammation and chronic
neuropathic pain (Marchand, Perretti, & McMahon, 2005). Non‐
neuronal astrocytes, satellite glia cells, microglia, and mast cells play
key roles in communication between the immune system and the
CNS via the production of neuroinflammatory mediators, including his-
tamine, 5‐HT, chemokines, and growth factors (Zhuang, Gerner, Woolf,
& Ji, 2005). The neuroimmune interactions between these two systems
may reflect distinct roles in the development of chronic neuropathic
pain (Zhao et al., 2017). Stimulation of H1 receptors via a
PKC/MAPK/MEK1 signalling pathway has recently been shown to
elicit release of the key pro‐inflammatory cytokines IL‐1β and IL‐6with,
subsequent, regulation of nerve growth factor release from astrocytes
(reviewed recently in Jurič, Kržan, & Lipnik‐Stangelj, 2016). Satellite
glial cells, prominent in the PNS, including the DRGs, with active roles
in persistent neuropathic pain are also known to secrete the cytokine
IL‐6 in the chronic constriction injury neuropathic pain model, but the
identity profile of the histamine receptor in these cells has yet to be
established (Dubový, Klusáková, Svíženská, & Brázda, 2010). Activated
microglia also release a myriad of pro‐inflammatory cytokines, including
notably, IL‐6, IL‐1β, and TNF‐α (Kempuraj et al., 2016; Mika,
Zychowska, Popiolek‐Barczyk, Rojewska, & Przewlocka, 2013). H3
and H4 receptor activation of primary and clonal microglia has been
shown to inhibit these cytokines (Ferreira et al., 2012).Mast cells are professional cellular suppliers of histamine and
contribute to the histamine‐based effects in neuropathic pain. For
example, mast cell depletion prevented mechanical allodynia in a
mouse model of postoperative pain (Kaur, Singh, & Jaggi, 2017).
Recently, it was shown that the administration of azelastine hydro-
chloride, a second‐generation H1 receptor antagonist and mast cell
stabilizer, blocked the development of mechanical allodynia and
inhibited mast cell degranulation in mice with oxaliplatin‐induced
mechanical allodynia pain. The H1 and H4 receptors are likely molecu-
lar players in this process (Sakamoto, Andoh, & Kuraishi, 2016). For
example, genetically silencing the H4 receptor inhibited the production
of IL‐1β for human mast cells (Ebenezer, Prasad, Rajan, Thangam, &
Transduction, 2018), and H4 receptor activation was shown to stimu-
late a number of cytokines, including IL‐6 (Jemima, Prema, & Thangam,
2014). In addition, while H1 and H2 receptor antagonism reduced
hypersensitivity following nerve injury, it is possible that histamine
released by mast cells contributes to the recruitment of neutrophils
and macrophages in neuropathic pain and, acting via these histamine
receptors, contributes to the regulation of hypersensitivity in this type
of chronic pain (Jaggi et al., 2017; Smith et al., 2007; Zuo et al., 2003).
There is an important aspect associated with H2 receptor antagonism,
which should be considered for its therapeutic potential in neuro-
pathic pain control. In vitro studies using CHO and HEK‐293 cells
identified time‐ and dose‐dependent up‐regulation of H2 receptors
upon long‐term exposure to H2 receptor antagonists (e.g., ranitidine),
which may underlie the development of tolerance after prolonged
clinical use of these ligands and result in the rebound hypersecretion
of gastric acid and anaphylaxis that can occur after withdrawal of
treatment (Allen, Chazot, & Dixon, 2018; Smit et al., 1996). Thus, side
effects linked to pharmacological tolerance may potentially compro-
mise long‐term efficacy and tolerability of H2 receptor antagonists in
neuropathic pain. Little is known about the role of the H3 receptors
in non‐neuronal cells in neuropathic pain states.
Overall, non‐neuronal cells play a key, but poorly, defined role in
the mechanisms underlying histamine‐mediated neuropathic pain.
We propose that neuronal H1 and H4 receptors (Ferreira et al.,
2012) may orchestrate these mechanisms, with IL‐6 and IL‐1β cyto-
kines as common denominator mediators. Further complications arise
from the recent observation that activated mast cells trigger microglial
activation (Zhang, Wang, Dong, Xu, & Zhang, 2016). These cell types
and their interactions may potentially go some way to explain the par-
adoxical effects of histamine ligands, particularly for the H4 receptor,
seen in animal pain models.5 | HISTAMINE AND ITS INTERACTION
WITH OPIOID SYSTEM IN NEUROPATHIC
PAIN
Interestingly, in neuropathic pain, high doses of opioids are required
to achieve pain relief, and pharmacological tolerance to analgesic
effect of opioids develops rapidly (Osikowicz, Mika, Makuch, &
Przewlocka, 2008). This phenomenon significantly restricts the clinical
usefulness of opioids. In addition, the misuse of and addiction to
14 OBARA ET AL.BJPopioids, including prescription pain relievers, morphine and heroin, as
well as synthetic opioids, such as fentanyl, is a serious international
crisis that affects public health as well as social and economic welfare
(Lipman & Webster, 2015).
An interaction between histaminergic and opioidergic systems
within the CNS was suggested nearly 30 years ago, through an obser-
vation that morphine administration resulted in the release of hista-
mine and its increased turnover in the periaqueductal grey
(Nishibori, Oishi, Itoh, & Saeki, 1985), suggesting that analgesia pro-
duced by opioids may be associated with the stimulation of histamine
receptors at the supraspinal level. There are also data suggesting that
ligands of histamine receptors may modulate the analgesic action of
opioids; however, the site and mode of this interaction differ
between the spinal or supraspinal level, and depend on the subtype
of histamine receptor involved (Mobarakeh et al., 2002; Mobarakeh
et al., 2006; Mobarakeh, Takahashi, & Yanai, 2009). Specifically, a
series of studies over the last two decades has shown that in H1,
H2, or H3 receptor‐KO mice, morphine‐induced antinociception was
significantly augmented when compared to the wild‐type controls in
models of acute pain. H1 receptor‐KO mice showed a reduced spon-
taneous nociceptive threshold as they responded to significantly
lower pain stimuli when compared to their controls (Mobarakeh
et al., 2002), while thresholds for pain perception in H2 receptor‐
KO mice were higher when compared to their corresponding controls
(Mobarakeh et al., 2006). Intrathecal administration of morphine in H1
and H3 receptor‐KO mice and i.c.v. morphine injection in H2
receptor‐KO mice produce enhanced analgesic effects (Mobarakeh
et al., 2002; Mobarakeh et al., 2006). Interestingly, pharmacological
blockade of H1 and H3 receptors by either intrathecal administration
of the first‐generation antihistamine chlorpheniramine (H1 receptor
antagonist) or thioperamide (H3 receptor antagonist, H3 /H4 receptor
inverse agonist), or H2 receptor antagonism, produced by zolantidine
(i.c.v. route), resulted in the potentiation of the morphine analgesic
effect (Mobarakeh et al., 2002; Mobarakeh et al., 2006). These
behavioural studies, in both KO mice and involving pharmacological
interventions, clearly demonstrated that blocking H1, H2 and H3
receptors in combination with morphine may have beneficial effects
on analgesia and suggested that endogenous histamine may exert
an inhibitory effect on morphine‐induced analgesia acting via H1
and H3 receptors at the spinal cord level and via H2 receptors at
the supraspinal level.
Importantly, the observations observed with H3 receptor‐KO mice
are consistent with a pharmacological study using a preclinical model
of neuropathic pain induced by chronic constriction injury of the sci-
atic nerve. Here, Popiolek‐Barczyk et al. (2018) showed that blockade
of H3 receptors by a selective antagonist (E‐162) significantly
enhanced morphine antinociception assessed with both mechanical
and cold stimuli. Pharmacological analysis of these effects revealed
an additive effect. Interestingly, Popiolek‐Barczyk et al. (2018) also
showed that TR‐7, a selective H4 receptor antagonist, significantly
enhanced morphine antinociception in neuropathic pain. This latter
study is the first demonstration of the involvement of H4 receptors
in the regulation of morphine efficacy in chronic pain.To the best of our knowledge, the literature does not provide evi-
dence for the mechanisms underlying histamine and opioid system
interactions, in relation to the modulation of morphine analgesic
effects. Given that the analgesic effects produced by modulation of
the activity of both the histamine and opioid systems could be associ-
ated with blocking SP release from peripheral nerve terminals (Barnes
et al., 1986; Przewłocki & Przewłocka, 2001), it is possible that an
interaction that would result in potentiation of analgesic efficacy of
morphine may involve, together with other possible mechanisms, the
inhibition of peripheral SP accumulation. Such an outcome may be
useful for the management of neuropathic pain, particularly when
peripheral administration of drugs is possible, thus affording reduction
of the undesired secondary effects associated with opioid administra-
tion and peripheral mechanisms of action (e.g., constipation). How-
ever, centrally acting drugs administered by peripheral routes should
be taken into consideration due to the potential serious interactions
related to their pharmacodynamics and central mechanisms of action.
For example, chlorpheniramine (a first‐generation H1 receptor antago-
nist) was reported to potentiate fentanyl‐induced sedation and respi-
ratory depression after surgery (Anwari & Iqbal, 2003).6 | CONCLUSIONS AND FUTURE
DIRECTIONS
Findings from the last two decades indicate that selective pharmaco-
logical antagonism of neurons expressing H3 receptors could provide
important and promising therapeutic approaches for the control of
mechanical and cold hypersensitivity in peripheral neuropathies
(Table 1). The analgesic effectiveness of H3 receptor antagonists/
inverse agonists was comparable to gabapentin and pregabalin, first‐
line treatments for neuropathic pain. Importantly, multiple examples
of behavioural, electrophysiological, and molecular evidence strongly
support the rationale for this neuropathic pain strategy, particularly
given their ability to modulate histamine levels as well as several
neurotransmitters critical for chronic pain processing. Moreover, the
recent registered approval of pitolisant (Wakix™), an antagonist/
inverse agonist of H3 receptors, for the treatment of narcolepsy in
patients, has opened the door for the potential use of H3 receptor
ligands for other conditions, including chronic neuropathic pain. How-
ever, due to the wide presynaptic and postsynaptic distribution of H3
receptors throughout the CNS and PNS, more research is certainly
needed to clarify the involvement of peripheral, spinal, and brain H3
receptors in various pain states, before determining their full potential
in neuropathic pain.
Recent findings also suggest the use of centrally permeable H2
receptor antagonists as promising new drug candidates for the treat-
ment of neuropathic pain, in view of their analgesic effects and meta-
bolic stability. Interestingly, however, despite the discovery of the
most recently discovered histamine receptor, the role of the H4 recep-
tor in neuropathic pain transmission is still controversial after nearly
20 years, with apparent confounding effects of both agonists and
antagonists on hypersensitivity associated with neuropathic pain. This
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ligands and differential effects on multiple signalling pathways in cen-
tral and peripheral parts of the sensory nervous system. Furthermore,
the paucity of detailed mechanistic definitions of histamine‐mediated
analgesia, and the additive effects with the opioid system, requires
attention to provide a rationale to the field of histamine and develop-
ment of neuropathic pain control therapeutics.
A better understanding of the interaction between histaminergic
signalling pathway molecules (Figures 1–3) and histamine receptors
may result in the identification of further novel pharmacological
targets to improve neuropathic pain control. The literature available
provides some evidence for potential pharmacological target mole-
cules. One potential strategy exploits the role of Ca2+ channels in
the regulation of cellular excitability associated with nociception
(e.g., N‐type Ca2+ channels). Evidence has shown that Ca2+ channel
blockers (e.g., ω‐conotoxin‐MVIIA/Prialt) offer interesting analgesic
potential in treating neuropathic pain (Vanegas & Schaible, 2000).
However, there is no evidence for the effect produced by a combina-
tion of Ca2+ channel blockers and histamine receptor ligands, and we
propose that their interaction should be taken into consideration.
Another potential target involves the contribution of the
MAPK/ERK signalling pathway to the regulation of pain hypersensi-
tivity. Recently, Sanna et al. (2015) showed that H4 receptor stimula-
tion, which led to analgesic activity in neuropathic pain, was
modulated by MAPK/ERK signalling in the neurons of the DRG,
spinal cord, and sciatic nerve. While the MAPK/ERK signalling path-
way regulates pain sensitivity and, for a while, has been considered
as a target for the treatment of neuropathic pain (Ma & Quirion,
2005), further studies on the interaction between this pathway and
H4 receptors may lead to the identification of more efficient thera-
peutic strategies to control neuropathic pain.6.1 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org/, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY (Harding et al., 2018), and are permanently archived in
the Concise Guide to PHARMACOLOGY 2017/18 (Alexander,
Christopoulos et al., 2017; Alexander, Fabbro et al., 2017; Alexander,
Peters et al., 2017; Alexander, Striessnig et al., 2017).ACKNOWLEDGEMENT
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